Navigation Links
Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
Date:4/28/2008

VEENENDAAL, The Netherlands, April 28 /PRNewswire/ --

- New Anatomy-Based Solution for HDR/PDR Brachytherapy Represents the Next Generation in DICOM-Compatible, Integrated Cancer Treatment Planning

Nucletron, a knowledge-based leader in radiation oncology, today announced the introduction of Oncentra(R) Brachy*, a comprehensive volume-based treatment planning system to optimize cancer treatment planning with brachytherapy. Oncentra Brachy, the world's first fully DICOM-compatible treatment planning system, features state-of-the-art optimization algorithms to ensure efficient treatment. The new solution provides excellent 3D contouring and margining tools to identify Regions of Interests (ROIs) on CT or in a multimodality imaging environments using image registration for CT, MR and PET data.

Oncentra Brachy provides many benefits to clinicians allowing for faster and easier creation of treatment plans, ranging from simple to complex, in user-defined workspaces that allow for adaptation to specific clinical workflows. Real-time information-sharing provides immediate access for the entire medical team and facilitates the exchange of treatment plans over vast distances with decentralized planning capabilities. Physicians are able to evaluate and authorize treatment plans remotely.

"The release of Oncentra Brachy marks the first of some new and exciting treatment planning innovations forthcoming from Nucletron," said Jeroen Cammeraat, chief operating officer of Nucletron. "We have set a new benchmark in technological achievement with Oncentra Brachy that represents the future of brachytherapy treatment planning. We have worked with our clinical partners to develop a state-of-the art solution that includes many sophisticated and powerful new tools to improve patient care."

"Oncentra Brachy opens new possibilities to explore new treatment techniques for brachytherapy planning that could not be considered before," according to the r
'/>"/>

SOURCE Nucletron B V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
2. Alfacell Announces Retirement of Chief Executive Officer
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
5. ATS Medical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
7. IDEXX Laboratories Announces First Quarter Results
8. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. ETEX Announces Supply Agreement with AlloSource
11. Wyeth Chairman Robert Essner Announces June 27 Retirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 03, 2015 , ... Sterlitech Corporation introduces the compact, quiet, ... analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free ... maintenance-free solution for a broad range of vacuum filtration applications. , Featuring a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Francois Vieillard as Sales & Marketing Director. , With more than 25 ... be responsible for reinforcing Tronics’ business development activities worldwide. He brings to the ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Life Technologies Corporation today announced that its Ion Personal ... Innovative New Product "MIP" Awards luncheon hosted by CONNECT in ... disruptive technology in the gene sequencing field. Since ... uptake in research labs around the world and has been ...
...  Puma Biotechnology, Inc., a development stage biopharmaceutical company, ... trials of Puma,s investigational drug PB272 (neratinib) were ... Cancer Symposium that is currently taking place in ... below: Safety and Efficacy ...
... MIAMI BEACH, Fla., Dec. 9, 2011  As hundreds ... at the International Society for Fertility Preservation,s 2nd ... in reproductive endocrinology, urology and oncology announced the ... coalition to help newly diagnosed cancer patients in ...
Cached Biology Technology:Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 2Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 2Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 4Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 6Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservation's 2nd World Congress 2Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservation's 2nd World Congress 3
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... burden of malaria remains the subject of "best guesses," ... remains "driven by perceptions and politics, rather than an ... in PLoS Medicine. , Simon Hay and Robert Snow ... that it has been almost 40 years since the ...
... in Fantastic Voyage, doctors might soon be able to ... find where and how much of a cancer treatment ... in a study published today in the open access ... and quantify molecules within individual mammalian or bacterial cells. ...
... a single gene, researchers can prevent skin stem cells from ... epidermal, sebaceous and hair cells. They say this finding could ... in the lab, for both research and potential therapies. , ... the ability to differentiate into multiple types of tissues, one ...
Cached Biology News:Fantastic Voyage: A new nanoscale view of the biological world 2Researchers identify a key regulator for skin stem cells 2
Request Info...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... Clone/PAD: 3B8A10. ... to the C-terminal region ... Specificity: Specific for the ... Reactivity: Human (positive control: ...
Biology Products: